122 related articles for article (PubMed ID: 36708301)
1. Positive hepatitis B core antibody is associated with advanced fibrosis and mortality in nonalcoholic fatty liver disease.
Zhang P; Liu Z; Fan H; Shi T; Han X; Suo C; Chen X; Zhang T
Eur J Gastroenterol Hepatol; 2023 Mar; 35(3):294-301. PubMed ID: 36708301
[TBL] [Abstract][Full Text] [Related]
2. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Chan TT; Chan WK; Wong GL; Chan AW; Nik Mustapha NR; Chan SL; Chong CC; Mahadeva S; Shu SS; Lai PB; Chan HL; Wong VW
Am J Gastroenterol; 2020 Jun; 115(6):867-875. PubMed ID: 32149781
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
4. Food Insecurity is Associated With Mortality Among U.S. Adults With Nonalcoholic Fatty Liver Disease and Advanced Fibrosis.
Kardashian A; Dodge JL; Terrault NA
Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2790-2799.e4. PubMed ID: 34958747
[TBL] [Abstract][Full Text] [Related]
5. The presence of hepatitis B core antibody is associated with more advanced liver disease in alcoholic patients with cirrhosis.
Zhang M; Wu R; Jiang J; Minuk GY; Niu J
Alcohol; 2013 Nov; 47(7):553-8. PubMed ID: 24041840
[TBL] [Abstract][Full Text] [Related]
6. The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999-2004.
Li L; Huang Q; Yang L; Zhang R; Gao L; Han X; Ji L; Zou X
Nutrients; 2022 Mar; 14(6):. PubMed ID: 35334881
[TBL] [Abstract][Full Text] [Related]
7. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
8. Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016.
Kim D; Kim W; Adejumo AC; Cholankeril G; Tighe SP; Wong RJ; Gonzalez SA; Harrison SA; Younossi ZM; Ahmed A
Hepatol Int; 2019 Mar; 13(2):205-213. PubMed ID: 30694445
[TBL] [Abstract][Full Text] [Related]
9. Impact of prior HBV, HAV, and HEV infection on non-alcoholic fatty liver disease.
Vassilopoulos S; Kalligeros M; Vassilopoulos A; Shehadeh F; Benitez G; Kaczynski M; Lazaridou I; Promrat K; Wands JR; Mylonakis E
J Viral Hepat; 2023 Aug; 30(8):685-693. PubMed ID: 37309229
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
[TBL] [Abstract][Full Text] [Related]
11. Antibody to hepatitis B virus core antigen positivity is a predictor of non-alcoholic fatty liver disease severity.
Saitta C; Caruso A; Maimone S; Filomia R; Cacciola I; Caccamo G; Franzè MS; Pitrone C; Alibrandi A; Gaeta M; Mandraffino G; Squadrito G; Raimondo G
Intern Emerg Med; 2022 Sep; 17(6):1609-1616. PubMed ID: 35332431
[TBL] [Abstract][Full Text] [Related]
12. Increased serum selenium levels are associated with reduced risk of advanced liver fibrosis and all-cause mortality in NAFLD patients: National Health and Nutrition Examination Survey (NHANES) III.
Reja M; Makar M; Visaria A; Marino D; Rustgi V
Ann Hepatol; 2020; 19(6):635-640. PubMed ID: 32745632
[TBL] [Abstract][Full Text] [Related]
13. The Association between Advanced Liver Fibrosis and Mortality Is Modified by Dietary Quality among Korean Adults: Results from the Korea National Health and Nutrition Examination Survey with Mortality Data.
Lee J; Jo G; Park D; Jun HJ; Bae JH; Shin MJ
Nutrients; 2023 Mar; 15(6):. PubMed ID: 36986234
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of High and Moderate Risk Nonalcoholic Fatty Liver Disease Among Adults in the United States, 1999-2016.
Golabi P; Paik JM; Harring M; Younossi E; Kabbara K; Younossi ZM
Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2838-2847.e7. PubMed ID: 34929391
[TBL] [Abstract][Full Text] [Related]
15. Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA.
Wijarnpreecha K; Kim D; Raymond P; Scribani M; Ahmed A
Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1121-1128. PubMed ID: 30888971
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States.
Le MH; Devaki P; Ha NB; Jun DW; Te HS; Cheung RC; Nguyen MH
PLoS One; 2017; 12(3):e0173499. PubMed ID: 28346543
[TBL] [Abstract][Full Text] [Related]
17. Association between handgrip strength, nonalcoholic fatty liver disease, advanced hepatic fibrosis and its modifiers: Evidence from the NHANES database of the USA.
Zhao X; Shi X; Gu H; Zhou W; Zhang Q
J Gastroenterol Hepatol; 2023 Oct; 38(10):1734-1742. PubMed ID: 36805682
[TBL] [Abstract][Full Text] [Related]
18. Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis.
Jung CH; Rhee EJ; Kwon H; Chang Y; Ryu S; Lee WY
Endocrinol Metab (Seoul); 2020 Mar; 35(1):165-176. PubMed ID: 32207277
[TBL] [Abstract][Full Text] [Related]
19. The Association Between Nonalcoholic Fatty Liver Disease and Metabolic Abnormalities in The United States Population.
Jinjuvadia R; Antaki F; Lohia P; Liangpunsakul S
J Clin Gastroenterol; 2017 Feb; 51(2):160-166. PubMed ID: 27580477
[TBL] [Abstract][Full Text] [Related]
20. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.
Angulo P; Bugianesi E; Bjornsson ES; Charatcharoenwitthaya P; Mills PR; Barrera F; Haflidadottir S; Day CP; George J
Gastroenterology; 2013 Oct; 145(4):782-9.e4. PubMed ID: 23860502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
